Very Low Density Lipoprotein (VLDL) Available to Researchers from Lee Biosolutions
Lee Biosolutions has announced the production and availability of very low density lipoprotein (VLDL) from human plasma for purchase at LeeBio.com.

/Biotechnology News Articles/ - ST. LOUIS, MO, March 17, 2007 - Lee Biosolutions has announced the production and availability of very low density lipoprotein (VLDL) from human plasma for purchase at LeeBio.com.

Very low density lipoprotein contains about 16%-22% cholesterol and high amounts of triglycerides, which can put people at risk for coronary heart disease. VLDL levels have also been correlated with accelerated rates of atherosclerosis, and are elevated in a number of other diseases and metabolic states.

According to Lee Biosolutions President Burton Lee, the company's recent addition of VLDL to their product line is an extension of their commitment to providing the latest materials in demand by the research community.

"We constantly keep an ear tuned to our customers and to the international research community as a whole," Lee said. "This helps us stay on top of the latest trends in research and assures that we're ready when we're called on to deliver."

Very low density lipoproteins inhibit DNA synthesis in lymphocytes activated by the nonspecific mitogen concanavalin A (Con A). VLDL is the next step down from chylomicrons in terms of size and lipid content. VLDL circulates through the blood giving up triglycerides to fat and muscle tissue until the VLDL remnants are modified and converted into LDL. The lipoprotein is produced in the liver.

According to the company, The VLDL donors are of US origin and have been tested and found to be negative for HbsAg, HCV, HIV-1 & 2, Syphilis and HIV-1 Antigen by currently approved FDA methods.

Press Release Contact Information:

Pat Watters
KolbeCo MArketing Resources
Acct. Manager
Website: Visit Our Website